Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, USA.
J Leukoc Biol. 2011 Feb;89(2):301-9. doi: 10.1189/jlb.0710402. Epub 2010 Oct 15.
Opioid receptor agonists induce broad immunomodulatory activity, which substantially alters host defense and the inflammatory response. Previous studies have shown that the MOR selective agonist DAMGO has the capacity to increase the expression of the proinflammatory chemokines CCL2, CCL5, and CXCL10 in human PBMCs. NF-κB is a transcription factor that plays a pivotal role in innate and adaptive immune responses. We report that NF-κB is a vital player in the DAMGO-induced, MOR-mediated regulation of chemokine expression. Results show that NF-κB inhibitors prevent the induction of CCL2 expression in response to DAMGO administration and that the NF-κB subunit, p65, is phosphorylated at serine residues 311 and 536 in response to MOR activation. Furthermore, we demonstrate that PKCζ is phosphorylated following DAMGO-induced MOR activation, and this kinase is essential for NF-κB activation as well as CCL2 expression and transcriptional activity. Finally, ChIP analysis shows that DAMGO administration induces binding of p65 to the enhancer region of the CCL2 promoter. These data are consistent with the notion that MOR activation promotes a proinflammatory response, which involves NF-κB activation. Our results also suggest a significant and novel role for PKCζ as an essential participant in the MOR-mediated regulation of proinflammatory chemokine expression.
阿片受体激动剂诱导广泛的免疫调节活性,这极大地改变了宿主防御和炎症反应。先前的研究表明,MOR 选择性激动剂 DAMGO 具有增加人 PBMCs 中促炎趋化因子 CCL2、CCL5 和 CXCL10 表达的能力。NF-κB 是一种在先天和适应性免疫反应中起关键作用的转录因子。我们报告 NF-κB 是 DAMGO 诱导的、MOR 介导的趋化因子表达调节中的重要参与者。结果表明,NF-κB 抑制剂可阻止 DAMGO 给药后 CCL2 表达的诱导,并且 NF-κB 亚基 p65 在 MOR 激活时在丝氨酸残基 311 和 536 处被磷酸化。此外,我们证明 DAMGO 诱导的 MOR 激活后 PKCζ 被磷酸化,并且该激酶对于 NF-κB 激活以及 CCL2 表达和转录活性是必需的。最后,ChIP 分析表明,DAMGO 给药诱导 p65 与 CCL2 启动子的增强子区域结合。这些数据与 MOR 激活促进促炎反应的观点一致,其中涉及 NF-κB 激活。我们的结果还表明,PKCζ 在 MOR 介导的促炎趋化因子表达调节中具有重要的新作用,是必需的参与者。